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While oxygen is critical to the continued existence of complex organisms, extreme
levels of oxygen within a system, known as hypoxia (low levels of oxygen) and
hyperoxia (excessive levels of oxygen), potentially promote stress within a defined
biological environment. The consequences of tissue hypoxia, a result of a defective
oxygen supply, vary in response to the gravity, extent and environment of the
malfunction. Persistent pathological hypoxia is incompatible with normal biological
functions, and as a result, multicellular organisms have been compelled to develop
both organism-wide and cellular-level hypoxia solutions. Both direct, including oxidative
phosphorylation down-regulation and inhibition of fatty-acid desaturation, and indirect
processes, including altered hypoxia-sensitive transcription factor expression, facilitate
the metabolic modifications that occur in response to hypoxia. Due to the dysfunctional
vasculature associated with large areas of some cancers, sections of these tumors
continue to develop in hypoxic environments. Crucial to drug development, a robust
understanding of the significance of these metabolism changes will facilitate our
understanding of cancer cell survival. This review defines our current knowledge base of
several of the hypoxia-instigated modifications in cancer cell metabolism and exemplifies
the correlation between metabolic change and its support of the hypoxic-adapted
malignancy.
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INTRODUCTION
Hypoxic regions, areas of reduced tissue oxygen levels, are found in many solid tumors occurring
as a consequence of the disordered vasculature developed to supply oxygen to the rapidly growing
tumor. In cancer patients tumor hypoxia leads to a poor prognosis (Vaupel, 2008) due to the
potential of increased malignancy, resistance to both chemotherapy and radiation treatment, and
an increased likelihood of metastasis (Höckel and Vaupel, 2001). In comparison to normal human
tissues where the oxygen tension typically exceeds 40 mmHg, in tumors an oxygen tension of 0–
20 mmHg may persist (Vaupel et al., 1989). Hypoxia typically arises in solid tumors at a distance of
approximately 100 µm from a functional blood vessel (Helmlinger et al., 1997).
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Tumor cells are exposed to a continuum of oxygen
concentrations and consequently solid tumors are comprised
of three tissue regions: the normoxic, hypoxic and necrotic
(Figure 1). Situated nearby functional blood vessels normoxic
cells are typically viable and proliferative. At distances of 150 µm
from patent blood vessels cells may become anoxic, giving rise
to patches of necrosis. Peri-necrotic cells are typically hypoxic
and capable of existing at very low oxygen concentrations
(PO2 ≤ 1%) (Hall and Giaccia, 2006). In normal cells, hypoxia
typically leads to cell death. Counter-intuitively, however,
hypoxia can induce genomic changes that enable tumor cells
to adapt to poor nutrition and the hostile microenvironment,
thus remaining viable. Consequently, hypoxia exerts a selection
pressure that leads to the survival of subpopulations of viable
cells with the genetic machinery for malignant progression
(Vaupel and Harrison, 2004). Tumors can overcome the
proliferation limitations posed by the stressful microenvironment
by stimulating the production of new blood vessels via the
release of hypoxia-inducible angiogenic factors, such as vascular
endothelial growth factor (VEGF) to develop a new blood supply
(Seo et al., 2014). Paradoxically, following neovascularization in
solid tumor tissue, which consists of poorly organized, elongated,
dilated, twisted and blind-ended blood vessels, oxygen supply for
the tumor may still be deficient (Helmlinger et al., 1997).
In human tumors hypoxia presents as one of two classes,
chronic or acute forms, based on the conventional categorization
common in research and medical oncology (Höckel and Vaupel,
2001; Vaupel et al., 2001). As noted by Vaupel et al. (2001)
and Vaupel and Harrison (2004), the structural and functional
abnormalities arising from the chaotic vasculature and structure
of a tumor, including dilated, elongated and twisted blood
vessels, poor endothelium, reduced functional cell receptors, no
regulation of blood flow, which results in spontaneous stasis,
result in poor oxygen delivery as a consequence of inadequate
blood flow. This form of hypoxia is termed ischemic hypoxia
and is generally transient (Vaupel et al., 2001; Vaupel and
Harrison, 2004). Chronic, diffusion-limited hypoxia results from
an imbalance of oxygen supply and demand due to an increase
in diffusion distance with tumor growth, where rapid tumor
expansion results in tumor tissue at distances further than 70–
150 µm from patent blood vessels receiving insufficient oxygen.
Occasionally, anemic hypoxia can arise, initiated by a decreased
capacity of the blood to transport oxygen when anemia is
induced by chemotherapy (Vaupel et al., 2001). Both acute and
chronic hypoxia are correlated with poor patient outcome and
an aggressive tumor phenotype (Williams et al., 2001; Vaupel and
Harrison, 2004).
CELLULAR RESPONSES AND
ADAPTATIONS TO HYPOXIA
Hypoxia induces both proteomic and genomic changes within
tumor cells (Figure 2). Proteomic changes may initiate cell cycle
arrest, differentiation, necrosis and apoptosis (Lee and Lin, 2017).
Additionally, hypoxia- induced proteomic changes may also
stimulate tumor growth, invasion and metastasis by facilitating
acclimatization and survival in a hostile, nutrient-deprived
environment (Vaupel and Harrison, 2004). At a molecular level,
the adaptation of tumor cells to hypoxic stress is regulated
largely by hypoxia-inducible factor (HIF), a transcription factor
which accumulates in response to decreased cellular oxygen levels
(Schito and Rey, 2017; Wolff et al., 2017).
HYPOXIA-INDUCIBLE FACTORS (HIFs)
THE KEY OPERATOR IN HYPOXIA
SIGNALING
Three human HIF family members have been identified, HIF-1,
HIF-2, and HIF-3, these heterodimers comprise of α subunit and
β subunit, which dissociate in normoxic conditions (Figure 3).
Of the three isoforms, HIF-1 is frequently overexpressed in
tumor cells (Weidemann and Johnson, 2008; Robinson et al.,
2017), with HIF-2 [endothelial PAS domain protein 1 (EPAS1)]
strongly expressed by subsets of tumor-associated macrophages
(Talks et al., 2000) and HIF-3 expressed in pulmonary alveolar
epithelial cells (Li et al., 2006) and in human kidney (Yang et al.,
2015). The most extensive characterization has been provided
for HIF-1α. Although the DNA binding and dimerization
domains of HIF-1α and HIF-2α are similar from a structural
perspective, the transactivation domains of these two forms are
dissimilar. This may be the reason for the genome wide screen
detection of the binding of both forms to identical (hypoxia-
response elements) HRE consensus sites, but with a different
transcriptional responses being activated (Mole et al., 2009).
Another difference is that HIF-1α has all-pervasive expression,
whereas HIF-2α expression is more limited to specific tissues (Hu
et al., 2003; Bhatia et al., 2013). On the whole, the two forms
react to hypoxia through different biological actions (Loboda
et al., 2010). To give an example, the transcription of genes that
encode enzymes participating in glycolysis is regulated solely by
HIF-1α as observed by Hu et al. (2003). By contrast, HIF-2α is
believed to play a role in adjustment to high altitudes (van Patot
and Gassmann, 2011). In the case of human colon cancer, HIF-
1α staining was strong whilst HIF-2α staining was weak in late
stage tumors, whereas the opposite has been documented in early
stage tumors. This phenomenon has prompted Imamura et al.
(2009) to deduce that the involvement of HIF-1α and HIF-2α in
human colon cancer was not the same (Imamura et al., 2009).
On the other hand, the transactivation domain is absent from
HIF-3α which means that this form possesses a suppressive effect,
preventing HIF-1α from initiating transcription by binding to it.
Due to this action, HIF-3α is also referred to as the ‘inhibitory
Per-Arnt-Sim PAS domain’ (IPAS) (Weidemann and Johnson,
2008).
The transcription of HIF-1α does not require oxygen,
however, in normoxia, HIF-1α is rapidly degraded (Kaelin et al.,
2016). Degradation of HIF-1α under normoxic conditions is a
ubiquitin-mediated process, activated by the tumor suppressor
protein pVHL (von-Hippel-Lindau protein). In contrast, ARNT
((Aryl Hydrocarbon Receptor Nuclear Translocator), also known
as HIF-1β) is not downregulated by oxygen and is constitutively
present. At low oxygen levels, HIF-1α is stabilized and
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FIGURE 1 | Hypoxic regions of solid tumors. Tumors contain regions of oxygenated cells situated near to blood vessels, becoming increasingly hypoxic with
increased distance from a functional blood supply.
FIGURE 2 | The role of hypoxia in the cancer-specific biological pathways. In hypoxic conditions, cancer cell metabolism undergoes a shift from oxidative
phosphorylation to aerobic glycolysis. Additionally, hypoxia regulates cell proliferation and supports evasion of apoptosis by the tumor cells. Furthermore, hypoxia
contributes to the changes that confer limitless replicative potential and to the expression of genes, allowing invasion, and metastasis.
translocates from the cytoplasm into the nucleus where it binds
to its heterodimeric partner ARNT, inducing a conformational
change and the formation of active HIF-1 (Zimna and Kurpisz,
2015). Over 100 genes are regulated directly and indirectly
by HIF (Goda and Kanai, 2012; Semenza, 2012a), the active
form of which binds to a HRE in the target gene promoter
region. These genes are implicated in a myriad of functions,
including the promotion of angiogenesis, erythropoiesis, cell
growth and proliferation, invasion/metastasis and metabolic
adaptation. Many of the genes induced by HIF-1 are highly
expressed in tumors relative to normal tissues, for example VEGF,
Glucose transporter 1, Glucose transporter 3, Insulin-like growth
factor binding protein-1 and -3, Insulin-like growth factor II,
Transforming growth factor-β3 and p21 (Maxwell et al., 2001;
Masoud and Li, 2015). In HIF induced angiogenesis, the extent
of neo-vascularization implicates HIF-mediated expression of
the two key angiogenic factors, VEGF-A and angiopoietin-2
(Brahimi-Horn and Pouysségur, 2007).
THE ROLE OF HYPOXIA IN CANCER
STEM CELLS (CSCS)
In common with normal adult stem cells (ASCs), cancer stem
cells (CSCs) are undifferentiated self−renewing cells able to
form a heterogeneous population of daughter cells. Under
atmospheric oxygen conditions (21%), in vitro stem cells lose
their stemness characteristics (Simon and Keith, 2008). In vivo,
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FIGURE 3 | Activation and degradation of the hypoxia inducible factor-1α (HIF-1α). In normoxia HIF-1α is rapidly degraded, while it accumulates in hypoxic
conditions. HIF-1α associates with HIF-1β and the resulting heterodimer binds to the hypoxia response element (HRE) of target genes.
ASCs are maintained in hypoxic conditions, typically defined as
1% oxygen; an example being haematopoietic stem cells (HSCs)
that reside in the hypoxic endosteal regions of bone marrow
(Kubota et al., 2008). CSCs also favor hypoxic sites within
tumors (Das et al., 2008), enabling the cells to maintain their
undifferentiated state. As with ASCs, differentiation occurs in
in vitro populations of cells under physiologically normal levels
of oxygen (Jögi et al., 2002; Heddleston et al., 2009).
The stimulation of cancer cell stemness by HIFs is well
documented, with studies revealing HIF-1α and HIF-2α to be
central to CSC stemness. Upregulation of HIF-1α, which heralds
CSC proliferation, is essential for CSC survival in hypoxic
conditions (Lau et al., 2017). HIF-2α is also key to CSC survival
and it co−localizes with CSC markers. HIF-1α and HIF-2α are
both essential for maintaining stem−like properties and CSC
survival (Li et al., 2009). The contributions made by HIF-1α
and HIF-2α in maintaining the stem−like state of CSCs differ
(Li et al., 2009). As previously mentioned HIF-1α binds to and
stimulates the genes for survival in low oxygen conditions, such
as those of the glycolysis pathway. On the other hand, the
target structures of HIF-2α are stem cell upkeep genes, including
Notch, octamer-binding transcription factor 4 (Oct4) and the
sex determining region Y-box 2 (Sox2). This differentiation of
function suggests that stemness may be influenced more by
HIF-2α than HIF-1α (Covello et al., 2006; Keith et al., 2012).
A significant challenge for clinicians treating cancer is
chemotherapy resistance leading to a poor therapeutic response,
and in turn, to relapse (Dean et al., 2005). One mechanism of
resistance can be attributed to the capacity of CSCs to evade and
resist chemotherapy by virtue of their stem cell qualities. CSCs
can adopt slow cycling growth, known as quiescence, enabling
the cells to avoid those therapies that target rapidly dividing cells;
additionally, the survival signaling pathways can be modified
preventing cell death (Clarke and Hass, 2006). Moreover, the
self-renewing capability of CSCs leads them to act as reservoir
cells, facilitating cancer reoccurrence (Clarke and Hass, 2006;
Holohan et al., 2013; Schöning et al., 2017). Using a murine
model Saito et al. (2010) used chemical stimuli to induce CSCs
present in the hypoxic endosteal region of the bone marrow to
enter the cell cycle. When combined with chemotherapy, the
survival of mice with leukemia was increased by this treatment
methodology (Saito et al., 2010). Thus, maintaining CSCs in
hypoxic microenvironments sustains the cells’ quiescent state
and consequently, they are able to resist most chemotherapy
interventions (Schöning et al., 2017).
THE ROLE OF HYPOXIA IN THE TUMOR
STROMA
Rather than only being determined by cancer cells,
cancer progression is the product of the entire tumor
microenvironment, including cancer cells, extracellular matrix
(ECM) and stroma (Hanahan and Coussens, 2012). Through
inhibition of the expression of Bid, the pro-apoptotic Bcl-2-
family protein, HIF-1 reduces apoptosis (Erler et al., 2004).
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HIF-1 also stimulates expression of survivin, an apoptosis
inhibitor (Peng et al., 2006). These mechanisms enable cancer
cells to endure; they are protected from the punishing hypoxic
environment and reduce the cells’ susceptibility to drug actions
(Erler et al., 2004).
The growth of cancer cells can result from autocrine
signaling. By having growth factor receptors on the membrane,
these cells can stimulate their own growth and survival by
secreting growth factors. During tumor development stromal
cells are in close proximity with cancer cells thus these
same growth factors modify the phenotypic behavior of
surrounding stromal cells to promote tumors (Semenza, 2012b).
Furthermore, cancer cell invasion and metastasis is promoted
by hypoxia. Under such conditions, cancer cells experience
greater motility and invasiveness by encouraging epithelial
to mesenchymal transition. The mechanism responsible for
this is upregulated expression of the transcription factors
Snail Family Transcriptional Repressor 1 (Snail1), Snail Family
Transcriptional Repressor 2 (Snail2), and Twist. As a result,
the expression of E-cadherin, which is a key component of
adherens junctions, is downregulated (Schwab et al., 2012).
Cancer-associated fibroblasts (CAFs) are primary tumor stroma
components (Cirri and Chiarugi, 2012; Lau et al., 2017). CAFs act
in a paracrine manner, encouraging tumor growth and sustaining
CSCs’ stemness property (Forsberg et al., 1993; Giannoni et al.,
2010). Research shows that CAFs are a heterogeneous population,
of which the majority adopt the activated phenotype, exhibiting
increased secretion of ECM, growth factors and proteases, greater
contractile force, and proliferation activity (Tao et al., 2017).
There are numerous origins of CAFs, varying with different
forms of cancer. Several studies reveal that by secreting signaling
molecules, cancer cells cause resting fibroblasts to become CAFs.
Such signals include basic fibroblast growth factor (bFGF),
interleukin-6 (IL-6), platelet-derived growth factor (PDGF) and
transforming growth factor beta (TGF-β) (Tao et al., 2017).
HIF-1 contributes to the behavior of normal fibroblasts
and CAFs; furthermore, HIF-1α demonstrates tumor-promoting
capability. Elevated tumor growth has been observed in studies
that use the active form of HIF-1α expressed by human skin
fibroblasts co-injected with MDA-MB-231 cells. The same effect
was not detected with HIF-2α. It is proposed that activating
HIF-1α initiates autophagy and aerobic glycolysis; this provides
cells surrounding the cancer cells with the energy necessary to
promote their growth (Chiavarina et al., 2010).
HIF HYDROXYLATION
Under conditions of normoxia, hydroxylation of the two proline
residues located in the oxygen dependent degradation domain
(ODDD) region by prolyl-4-hydroxylase domain (PHD) enzyme
and lysine (Lys532) acylation by acetyl-transferase-arrest-
defective-1 (ARD-33 1) enzyme activity (Dengler et al., 2014)
destabilizes the HIF-α subunits. Subsequent to hydroxylation
and acetylation, HIF-α is identified by p-VHL tumor suppressor
resulting in poly-ubiquitination by E3 ubiquitin-ligase; and
this complex is then further degraded by proteasome 26S
(Masoud and Li, 2015). A further hydroxylation reaction takes
place on Asparagine 803 on the C-terminal domain of HIF-
α. This hydroxylation is due to factor inhibiting HIF (FIH),
which restricts co-activation with p300, thereby inhibiting
HIF transcriptional activation (Masoud and Li, 2015). Prolyl-
hydroxylase and asparagine hydroxylase are both members
of the oxygen-dependent hydroxylase families whose catalytic
properties are dependent upon oxygen, and are viewed as
the cellular detectors for oxygen concentration (Schofield and
Ratcliffe, 2004). Under hypoxic conditions, the absence of
oxygen, which constitutes the substrate for PHDs and FIH,
results in a cessation of the hydroxylation process, preventing
the binding of HIF-α to the p-VHL (Arsenault et al., 2015;
Maxwell et al., 2017). This leads to the build-up of HIF-1α in
its stable isomer, translocation across the nuclear membrane and
binding to the β- subunit to generate the active HIF dimer. This
subsequently binds to co-activators, e.g., CREB-binding protein
CBP/p300, transcription intermediary factor 2 and steroid–
receptor activator activators to up-regulate gene transcription
(Ke and Costa, 2006; Luo et al., 2011).
Prolyl-4-hydroxylase domain enzyme activity represents the
connection between oxygen sensing and energy generation by
the Kreb’s Cycle. Secondary metabolites of the Kreb’s Cycle
are key to the PHDs activity, whilst end-products of the
Kreb’s Cycle (e.g., succinate and fumarate) inhibit PHD enzyme
activity (Isaacs et al., 2005; Koivunen et al., 2007). Mutations
involving metabolic genes [e.g., fumarate hydratase (FH), the
subunits of succinate dehydrogenase (SDH), and isocitrate
dehydrogenase (IDH1 and IDH2)] can give rise to a condition
termed pseudo-hypoxia by formation of a reduced variety of
2-oxoglutarate, (R)-2-hydroxyglutarate, as an oncometabolite,
involving activation of HIF-1, irrespective of a normal oxygen
environment (Chowdhury et al., 2011; Koivunen et al., 2012).
At least four isoforms of the prolyl hydroxylase domain
enzyme (PHD1-4) have been identified so far in mammalian
tissues. The PHDs all possess a double strand β-helix core fold,
which are also termed jelly roll folds (Karuppagounder and
Ratan, 2012). All PHD isoforms are able to hydroxylate the
LXXLAP motif in HIF-α subunits and this sequence is also
present in other molecules, including the nuclear factor of kappa
light polypeptide gene enhancer in B-cells inhibitor (IκBα), RNA
polymerase and β-adrenergic receptors (Fong and Takeda, 2008).
The HIF mechanism is halted under conditions of normoxia
by the inhibitory influence of PHD, whilst under conditions of
hypoxia; PHDs are inactive, resulting in an active HIF pathway
(Fong and Takeda, 2008). PHDs are viewed as the cellular oxygen
sensor, because they express a high affinity to oxygen, possessing
a Km-value within the 230–250 µM range, when compared with
alternative hydroxylase enzymes, such as collagen hydroxylase
(Olcina et al., 2018). So as to ensure optimum activity, PHDs
have a requirement for oxygen molecules: one oxygen atom
combines with proline to produce hydroxyl-proline and the
other oxygen atom is utilized for de-carboxylation of 2-OG to
produce succinate (Gerald et al., 2004). Furthermore, the PHDs
also need non-haem-Fe2+ in order to engage in catalytic activity;
which binds to the His-X-Asp/Glu-Xn-His motif to promote such
enzymatic activity. In addition, the PHD also requires ascorbic
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acid to recycle Fe2+ to its active form (Hancock et al., 2015). The
activity of PHDs is inhibited by hypoxia, nitric oxide, ROS, 2-OG
analogs and cobalt chloride (Maxwell et al., 2017).
Prolyl-4-hydroxylase domains can be inhibited through
multiple methods under normoxic conditions: via disruption
of the Fe2+ equilibrium by application of an iron chelator such
as deferoxamine (DFO) or via application of a competitive
inhibitor, such as cobalt chloride (Deppe et al., 2016). These
non-specific chemicals result in the potential for off-target effects
to be significant (Deppe et al., 2016). An alternative approach
for modulation of PHDs activity is via application of 2-OG
analogs, including: L-Mimosine (L-Mim); dimethyloxalyl-glycine
(DMOG); 3,4-dihydroxybenzoate (3,4-DHB); and N-[[1,2-
dihydro-4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]
carbonyl]-glycine (IOX2). IOX2 possesses significantly greater
potency than DMOG, where relative IC50 values are 0.022 µM
and 5 µM respectively. IOX2 is able to inhibit both PHD-2 and
FIH with greater than 5000 times the selectivity for PHD-2 than
histone demethylases (Chowdhury et al., 2013).
EPIGENETIC INTERACTIONS WITH THE
METABOLISM OF TUMOR CELLS
Gene expression is dramatically influenced by metabolic changes
which are associated with cancer. Whilst metabolite profiles may
not have much influence at the genetic level, it would seem that
they do exert a significant influence on epigenetic regulation of
gene expression. Epigenetic factors can be defined as heritable
factors, which in this case influence gene expression, without
requiring modification of DNA sequences (Wong et al., 2017).
Such epigenetic regulation of gene expression can be extremely
malleable in response to a wide variety of environmental
parameters (Herceg and Vaissière, 2011; Feil and Fraga, 2012).
Epigenetics fundamentally involves the chemical alteration of
DNA and histone molecules and constitutes a mechanism
which inherently connects nutritional state with gene expression.
Consequently, it is possible for metabolic changes to override
the epigenomic apparatus within cancer cells (Gupta et al., 2014;
Johnson et al., 2015). Similarly, epigenetic deregulation in cancer
at least partly facilitates altered gene expression (Wong et al.,
2017).
Epigenetics and metabolism in cancer are connected
by four interlinking pathways: (1) metabolic rewiring may
influence the required cofactor availability for epigenetic
enzyme alteration; (2) oncometabolites functioning as agonists
and/or antagonists for such epigenetic enzyme alteration may
be generated, influencing the epigenetic environment; (3)
conversely, epigenetic dysfunction can directly alter metabolism
by influencing metabolic enzyme expression; (4) the signal
transduction cascades contributing to the regulation of cellular
metabolism may be altered (Wong et al., 2017). The role played
by epigenetics in cellular responses to hypoxia is becoming
widely acknowledged. This type of epigenetic control may
function in tandem with the HIFs or, may provide a robust
pathway for the maintenance of a hypoxia-adapted cellular
phenotype for some time following the HIF initiation of
immediate response mechanisms. This includes: the part played
by epigenetics in both the stabilization and bonding of HIF to its
transcriptional targets; the part played by histone demethylase
enzymes subsequent to direct HIF transactivation; and, the effect
of a hypoxic mileau on global histone modification responses
and DNA methylation (Watson et al., 2010). There is growing
support for the suggestion that HIF activity is superimposed
over a background of epigenetic alterations which are a
prerequisite for assessing any hypoxic response. In particular,
epigenetic alterations, at both the level of the DNA and histones
proffer the capability to specify HIF binding to target gene
promoters. Furthermore, hypoxia is inherently a potent inducer
of chromatin remodeling by regulating enzymes responsible for
DNA methylation modulation and histone alterations (Watson
et al., 2010). It is also critical to observe that chronic hypoxia can
lead to alterations in gene expression which remain independent
of the classical HIF mechanism. This can take place via changes
in the methylation status of gene sequences or, changes to the
normoxic histone code, potentially via prolonged modifications
to epigenetic altering enzymes (Watson et al., 2010; Vanharanta
et al., 2013). At the moment, there are four different views
on the relationship between epigenetics and hypoxia: (1) HIF
stabilization is affected by the epigenetic control of VHL and
PHD3 expression; (2) epigenetic pathways control HIF binding
by ensuring a transcriptionally active chromatin configuration
in and in the vicinity of HIF binding sites (this may be due
to the HIF-1α coactivation complex or to direct changes to
the HRE binding sites, thereby preventing HIF binding); (3) a
major proportion of histone demethylase enzymes are direct
HIF-1 target genes which consequently play a major part in
the control of transcription during responses to hypoxia; (4)
major wide-reaching changes in histone alterations and DNA
methylation take place following exposure to hypoxia (Watson
et al., 2010; Wong et al., 2017).
THE INFLUENCE OF EPIGENETICS IN
HIF-α STABILIZATION CONTROL
Susceptibility to VHL-dependent ubiquitination and degradation
is conferred by PHD-dependent hydroxylation of HIF-α under
aerobic conditions (Hatzimichael et al., 2009). VHL tumor
suppressor gene mutations in humans are known to result
in a predisposition to a range of tumors, such as renal cell
carcinoma, hemangioblastoma of the central nervous system,
and phaeochromocytoma. Furthermore, VHL loss of function
mutations have been extensively investigated revealing that
expression of VHL can be blocked by promoter hypermethylation
in renal cell carcinoma and multiple myeloma (Hatzimichael
et al., 2009). Loss of VHL expression, as a consequence
of promoter hypermethylation, potentially represents a key
epigenetic mechanism which can lead to exacerbation of HIF
activity (Hatzimichael et al., 2009, 2010). The original suggestion
that the hypoxic response is largely dependent upon the
cooperation of epigenetics was proposed following examination
of the HIF-1α coactivation complex, where a number of
epigenetic modifying enzymes were identified in direct contact
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with HIF-1α during the initial cellular hypoxic response. It
is known that the histone acetyltransferase enzyme CBP/p300
directly associates with HIF-1α and takes part in the coactivation
of a network of hypoxia-inducible genes (Kallio et al., 1998;
Watson et al., 2010). Whilst many of the current perspectives
on the relationship between hypoxic response and epigenetic
mechanisms concentrate on the known interactions with HIF-
1α, it is considered that epigenetics is likely to have additional
important roles relating to cell adaptation and survival under
chronic hypoxic conditions subsequent to the initial HIF-
1α-induced cellular response (Watson et al., 2010; Vanharanta
et al., 2013; Hancock et al., 2015).
CHANGES IN METABOLISM THAT ARE
CONDUCIVE TO REDOX STATUS
Every cell produces reactive oxygen species (ROS), a varied
group of radical species constituting a normal by-product of
metabolic activities. The attributes and downstream effects of
ROS vary according to the levels in which these radical species
occur. When their concentration is low, ROS subject kinases and
phosphatases to post-translational alterations, thus stimulating
cells to proliferate and survive (Giannoni et al., 2005; Cao
et al., 2009). NADPH and NADPH oxidase (NOX) are usually
responsible for production of ROS in low concentration, which is
necessary for signaling events associated with homeostasis. When
their concentration is moderate, ROS trigger the expression of
stress-responsive genes (e.g., HIF-1α) (Gao et al., 2007; Chandel,
2010).
A notable incongruity is the fact that stabilization and
activation of HIF-1 are associated not only with conditions
of reduced levels of oxygen, but also with ROS. Guzy et al.
(2005) reported that under normoxia HIF-1α was stabilized
and the expression of HRE-reporter constructs was increased
when hydrogen peroxide was added. Furthermore, under the
same conditions of normoxia coupled with addition of hydrogen
peroxide, HRE-luciferase reporter activity can be displayed
by Hep3B cells, which lack mitochondrial electron transport
function (Chandel et al., 2000). Meanwhile in a different study,
breast tumor cells from mouse models were exposed to nitric
oxide as a way of demonstrating the molecular basis of HIF-
1 stabilization by ROS. Under normoxia, a particular cysteine
residue in the Oxygen-dependent degradation ODD domain of
HIF-1α underwent nitrosylation when nitric oxide was added.
In this way, the binding of the von Hippel-Lindau (VHL)
protein to HIF-1α was not possible and as a result, HIF-1α did
not deteriorate (Weidemann and Johnson, 2008). Involvement
in the HIF-1 signaling pathway under conditions of oxygen
deficiency (hypoxia) is an additional function that is thought to be
undertaken by ROS. As has been reported by several researchers,
e.g. (Guzy et al., 2005; Mansfield et al., 2005) the cells that did
not have functional mitochondria, and implicitly had low levels of
ROS, failed to achieve stabilization of HIF-α under circumstances
of hypoxia. Furthermore, it was observed that HRE-luciferase
reporter activity was diminished when excessive expression of
catalase in human 293 cells suppressed hydrogen peroxide under
hypoxia; what was implied from this was that HIF-1α activity was
reduced, and therefore hydrogen peroxide was added in order
to recover it. This may be related to fact that HIF participates
in ROS regulation while ROS play a role in HIF expression and
activity (Kotake-Nara and Saida, 2007; Owusu-Ansah et al., 2008;
Zeng et al., 2011). The conclusion that has been derived from such
observations was that, under conditions of hypoxia, HIF-1α could
only be stabilized if hydrogen peroxide was present in the cytosol
(Chandel et al., 2000).
Earlier research has demonstrated that ROS inactivate PHDs
via oxidation of the ferrous ion which is required for their
catalytic mechanism, thereby stabilizing HIF-1α (Yang et al.,
2014). Vitamin C has been demonstrated to reduce HIF-1 levels
by blocking the oxidation of the catalytic ferrous ion (Gao et al.,
2007; Calvani et al., 2012). Furthermore, it has also been recently
reported that the anti-carcinogenic influence of antioxidants,
such as N-acetyl cysteine (NAC) and vitamin C, are without
doubt HIF-1-dependent in murine simulations of Myc-mediated
tumor genesis (Calvani et al., 2012). Earlier research has also
demonstrated that under conditions of hypoxia, melanoma cells
are subject to constant oxidative stress as a consequence of raised
intracellular levels of ROS, resulting from mitochondrial complex
III deregulation (Comito et al., 2011). Mitochondrial ROS have
been found to play a predominant role in ROS formation and
subsequent HIF-1 stabilization in hypoxic environments (Bell
et al., 2007), as well as under non-hypoxic situations (Patten et al.,
2010). In addition to mitochondria, NADPH oxidases have also
been identified as playing a significant part in ROS generation and
in redox-dependent HIF-1 stabilization (predominantly under
normoxic conditions) (Lee et al., 2011). Calvani et al. (2012)
demonstrated that production of hypoxic ROS is a primary
role for HIF-1 stabilization, and activation of its transcriptional
response (Calvani et al., 2012). This was demonstrated by
showing how hypoxia evokes a redox-dependent stabilization of
HIF-1 in rat phaeochromocytoma PC12 cells, which subsequently
depends upon NADPH oxidase-driven ROS, Ca2+ and the
mammalian objective of rapamycin (mTOR) signaling (Calvani
et al., 2012). Enhancing ROS production under conditions of
hypoxia may initiate a redox adaptation response which allows
cancer cells to survive, as a consequence of raised tolerance
to exogenous stress, up-regulation of survival molecules and
enhanced drug inactivation capabilities (Pagé et al., 2008).
THE ROLE OF HYPOXIA-REGULATED
MicroRNAs IN CANCER METABOLISM
MicroRNAs (miRNAs) are small, endogenous RNA molecules;
they measure 18–24 nucleotides in length, and occur in
eukaryotes only. They do not code proteins, but regulate
post-transcriptional and translational gene expression. These
molecules have multiple actions contributing to diverse normal
and pathological cellular processes, including cell death,
development, metabolism, neuronal patterning and oncogenesis
(Pocock, 2011; Yu et al., 2012; Agrawal et al., 2016). Research
indicates that a group of microRNAs are regulated by HIF-1,
and in other instances, HIF-1 is the target of microRNAs. Many
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aspects of tumorigenesis are attributed to the interaction between
microRNAs and HIF-1; such aspects include angiogenesis,
apoptosis, cell cycle regulation, metabolism, metastasis,
proliferation and anticancer therapy resistance (Crosby et al.,
2009; Fasanaro et al., 2009; Shen et al., 2013). Other studies that
use the microarray method reveal that in a hypoxic environment,
different miRNAs are expressed (hypoxia- regulated miRNAs;
HRMs). Some miRNAs, such as miR-210, -155, -372/373, and
-10b, are up-regulated in hypoxia (Crosby et al., 2009; Neal
et al., 2010; Loayza-Puch et al., 2010; Bruning et al., 2011);
in contrast, miR-20b and miR-200b were down-regulated in
hypoxic conditions (Chan et al., 2011). The α and β subunits
of HIF-1 may adjoin both ends of the HRE in the promoter
regions of HRM genes. In hypoxia, the affinity between the HIF-1
subunits and HRE can intensify, causing the transcription of
HRMs to increase. HIF-1 regulates the expression of a number
of HRMs, including miR-210, -155, and -373, by modulating
HREs (Huang et al., 2009; Bruning et al., 2011). It has recently
been discovered that in hypoxic conditions, miR-210 regulates
mitochondrial metabolism. A number of researchers have
shown that the function of miR-210 is to inhibit parts of the
mitochondrial electron transport chain (ETC) complexes stages,
causing mitochondria to switch from oxidative phosphorylation
to glycolysis (Fasanaro et al., 2009; Huang et al., 2009; Chen et al.,
2010; Favaro et al., 2010). miR-210 targets the iron-sulfur cluster
scaffold homolog and cytochrome c oxidase assembly factor
(COX10) proteins, inhibiting mitochondrial respiration. Other
important cell metabolism structures that are the target of miR-
210 include GPD1-L (Favaro et al., 2010), NADH dehydrogenase
(ubiquinone) 1 alpha sub-complex 4 (NDUFA4) (Giannakakis
et al., 2008), and succinate dehydrogenase complex (Puissegur
et al., 2011).
HIF-1-INDUCED METABOLIC
ADAPTATIONS
Metabolic alterations were among the first biochemical
distinctive feature of cancer cells to be discovered and increased
understanding of tumor metabolism enables the elucidation of
novel targets and informs the development of new anticancer
therapies (Koukourakis et al., 2006; Giatromanolaki et al., 2017).
The difference between normal tissue and cancer metabolism
was first noted in the 1920s; with healthy cells, in normoxic
conditions, glucose is broken down into pyruvate, which is then
further catabolised via the tricarboxylic acid cycle and oxidative
phosphorylation in the mitochondria. In normal cells, the rate
of glycolysis is suppressed by the presence of oxygen (Pasteur
effect). Mitochondrial activity maintains elevated levels of ATP,
this leads to allosteric inhibition of the enzyme responsible for
glycolysis, phosphofructokinase (PFK) (Alfarouk et al., 2014).
In hypoxic conditions the end product of anaerobic glycolysis is
pyruvate that is then metabolized to lactate. Tumors, in contrast
to non-malignant tissue, tend to rely heavily on an increased
rate of glycolysis to support their energy demands even when
oxygen is plentiful, a phenomenon termed aerobic glycolysis or
the Warburg Effect (Liberti and Locasale, 2016) (Figure 4).
Warburg (1930) noticed that, compared to normal cells, tumor
cells exhibited higher glucose metabolism rates and preferentially
utilized glycolysis over oxidative phosphorylation, even when
oxygen levels were adequate (House et al., 1956; Warburg,
1956). Since then, a wide range of types of tumors have been
found to manifest aerobic glycolysis and evidence has been
accumulated that cancer progression is accompanied by an
overall restructuring of metabolism (Fritz and Fajas, 2010).
The influence of HIF-1α on glycolytic metabolism is well
established (Maxwell et al., 2001); glycolysis in tumors could
possibly be driven by HIF-1α stabilization, independently of
the hypoxic environment. According to an earlier survey of
cancer cell lines, there was about a 50% incidence of HIF-
1α stabilizing under normoxic conditions in cancers (Welsh
et al., 2004; Robey et al., 2005). Further to this the enzymes
responsible for the shift in metabolism by the repression of
oxidative phosphorylation and promotion of anaerobic glycolysis
are controlled by HIF-1α (Weidemann and Johnson, 2008;
Danquah et al., 2011). HIF-1α initiates over-expression in tumor
cells and raises the activity of a number of glycolytic protein
isoforms which are different to those present in non-malignant
cells. Such isoforms include: adenylate kinase-3; aldolase-
A,C (ALDA,C); carbonic anhydrase-9; enolase-1 (ENO1);
glucose transporter-1,3 (Glut-1,3); glyceraldehyde phosphate
dehydrogenase (GAPDH); hexokinase 1,2 (HK1,2); lactate
dehydrogenase-A (LDHA); phosphofructokinase L (PFKL);
phosphoglycerate kinase 1 (PGK1); and 6-phosphofructo-2-
kinase/gructose-2,6-bisphosphate-3 (PFKFB3); (Ke and Costa,
2006; Semenza, 2010).
Hypoxia-inducible factor directly up-regulate the genes
coding for glucose transporters such as Glut-1 and the enzymes
of the glycolytic pathway. HIF-1α induces the expression of
pyruvate dehydrogenase kinase 1 (PDK1), which phosphorylates
and consequently inhibits pyruvate dehydrogenase (PDH) (Kim
et al., 2006), which converts pyruvate to acetyl-CoA. Reduced
PDH activity under hypoxic conditions decreases the entry of
acetyl-CoA into the Krebs cycle, reducing the amount of substrate
available for downstream mitochondrial respiration and as a
result, oxygen consumption. Additionally, HIF-1α enables cells
to regulate to the reduced intracellular pH that occurs as a
consequence of increased anaerobic glycolysis and the resulting
lactic acid production (Weidemann and Johnson, 2008).
In a previous analysis of RT-qPCR data, the mRNA expression
of the HK-1 and 2, PKM-2, LDH-A, and Glut-1 genes,
has demonstrated cross tissue variation in expression and
correlations with clinical or pathological characteristics. Degrees
of expression of Glut-1, LDH-A, HK-1, PKM-2 and VDAC-
1 mRNA were observed to be significantly greater in primary
tumor/liver metastasis tissues relative to normal tissue mucosa
(Graziano et al., 2017).
A significant contributing mechanism responsible for this
aberrant behavior is believed to be mitochondrial dysfunction
(Chandra and Singh, 2011; Owens et al., 2011). Mitochondria
are highly dynamic organelles. Mitochondrial morphology is
regulated by fission/fusion mechanisms, which are modulated
according to changes in oxygen availability. Under hypoxia,
faster glucose consumption occurs in an attempt to maintain
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FIGURE 4 | Anaerobic glycolysis. Glycolysis provides two ATP molecules and does not require oxygen. One glucose molecule is converted into two pyruvate
molecules, which are subsequently fermented to two lactic acid molecules.
ATP production using less efficient anaerobic glycolysis (Lum
et al., 2007) and a shortage in the provision of substrates like
acetyl-CoA and O2 to mitochondria induces major structural,
functional, and dynamical changes. The structural and dynamical
changes are characterized by impairment of fusion process that
leads to mitochondrial depolarization, loss of mitochondrial
DNA (mtDNA) that may be associated with altered respiration
rates, and uneven distribution of the mitochondria within
cells (Jezek and Plecitá-Hlavatá, 2009). Under continuous
hypoxia, neurons have reduced mitochondrial size and altered
mitochondrial morphology, possibly in accordance with changes
in the activity of nitric oxide synthase (Guo et al., 2008). As
described by López-Ríos et al. (2007) and Moreno-Sánchez
et al. (2007), many alterations in mitochondria expression and
function are associated with the increased rate of glycolysis
in rapidly expanding tumors. In addition to a decrease in
the number of mitochondria within the cells, there is an
associated decrease in expressed levels of oxidative enzymes and
transporters, and conversely, an increase in a protein (IF1) which
inhibits mitochondrial ATP synthase. Furthermore, activation of
glycolysis results in lower levels of oxidative phosphorylation
(López-Ríos et al., 2007; Moreno-Sánchez et al., 2007). The
increase in the rate of glucose metabolism through aerobic
glycolysis is significant, with the rate of lactate production from
glucose being between 10 and 100 times greater than total
oxidation of glucose in mitochondria. However, the quantity of
ATP synthesized in a given period of time is similar regardless
of the form of glucose metabolism used (Shestov et al., 2014;
Liberti and Locasale, 2016). Several factors contributing to the
switch to aerobic glycolysis in various cancer types were identified
by Zheng (2012) and included oncogene activation, tumor
suppressor loss, the hypoxic microenvironment, mutations in
mtDNA and the tissue of origin (Zheng, 2012).
Aerobic glycolysis exhibits a number of essential, but poorly
understood, benefits which facilitate the preference for glycolysis
rather than mitochondrial oxidation in cancer cells, despite
the stoichiometric indication that mitochondrial oxidation is
required to maintain high glycolysis rates (De Souza et al., 2011).
Production of vital secondary metabolites for generation of lipids,
proteins and nucleic acids to promote cancer cell development
and proliferation is a key role for aerobic glycolysis (Graziano
et al., 2017). Tumors may benefit from the cell-independent
effects of lactate production, as lactate may interfere with
normal tissue structure, thus making tumor cells more invasive
(Locasale and Cantley, 2010). While a correlation between rates
of glycolysis and tumor aggressiveness has been demonstrated
in vitro, not all tumor cell types depend on glycolysis for
ATP generation. Some tumor types utilize both glycolysis and
oxidative phosphorylation, or some completely on oxidative
phosphorylation for ATP supply (Moreno-Sánchez et al., 2007;
Zheng, 2012). The evidence of this correlation is demonstrated in
comparing the non-invasive MCF7 breast cancer cell line (non-
invasive), which has much lower glucose consumption with the
more aggressive and highly invasive MDA-MD-231 breast tumor
cell line (Gatenby and Gillies, 2004). The conversion of glucose
into pyruvate and then lactate leads to a lowering of intracellular
pH, which is countered by the export of lactate from the cell,
causing extracellular acidification and consequently suppression
of the anticancer immune response (Locasale and Cantley, 2010).
Tumor- associated fibroblasts express the monocarboxylate co-
transporters MCT1 and MCT4, which transport important
monocarboxylates such as lactate and pyruvate (Koukourakis
et al., 2006). Lactate can be sequestered by stromal cells through
the monocarboxylate transporters to regenerate pyruvate that
either can be used for oxidative phosphorylation or can be used to
refuel the cancer cell through the lactic acid cycle (Koukourakis
et al., 2006).
Successful treatment approaches have so far not been
accomplished, despite endeavors to use compounds like 2-
deoxyglucose to inhibit aerobic glycolysis in cancer cells.
Suppression of lactate dehydrogenase and the blocking of
monocarboxylate transporters carrying lactate over the plasma
membrane are among the novel treatment strategies, with
multiple targets in the glycolytic process that are presently
being assessed (Fantin et al., 2006; Le et al., 2010). There
are a number of methods of disrupting glycolysis; developing
glycolytic inhibitors capable of acting with very high specificity
is a target for the pharmaceutical industry that may translate into
a clinical success (Ganapathy-Kanniappan and Geschwind, 2013;
Ganapathy-Kanniappan et al., 2013).
GLUCOSE TRANSPORTERS (GLUTS)
Glycolysis produces only two molecules of ATP from a single
molecule of glucose, compared with oxidative phosphorylation,
which produces 36 ATP molecules; cancer cells therefore demand
high fluxes of glucose to make up for this shortfall and satisfy
their energy demand (Alberts et al., 2008). Almost all mammalian
cells utilize glucose as a major source for energy and ATP
generation. Glucose is also a vital substrate for the synthesis of
triglycerides, glycoproteins and glycogen (Martinez-Outschoorn
et al., 2017). Tissue specific glucose transport is conducted
via the 13 facilitative glucose transporter family (Glut/SLC2A)
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members, which vary by their mode of regulation and affinities,
for example, Glut-5 transports fructose (Palm and Thompson,
2017). This process enables the facilitative glucose transporters
to maintain the glucose concentration gradient, an energy-
independent process, ensuring a continuous source of glucose
for metabolism (Zhou et al., 2017). Gluts are overexpressed
in solid tumors and are directly linked to a poor prognosis
in cancer patients. The Glut-1 isoform is overexpressed in a
variety of malignant neoplasms, including brain, hepatic, and
pancreatic tumors (Shibuya et al., 2015; Barron et al., 2016)
and correlates with tumor aggressiveness and poor prognosis
(Kunkel et al., 2003). Glut-1 overexpression also correlates with
tumor grade and distance from stromal blood supply, which
suggests a link with tumor hypoxia (Mendez et al., 2002). In
support of this hypothesis it has been found to be abundantly
expressed in hypoxic regions surrounding necrotic foci of breast
and colorectal cancers (Chen et al., 2017). Prolonged hypoxia
induces the expression of Glut-1 via the inhibition of oxidative
phosphorylation and upregulation of HIF-1 (Giatromanolaki
et al., 2017).
Researchers including Suh and Han (2013) and Ancey et al.
(2018) have shown that Glut-1 synthesis and transfer to the cell
membrane are positively influenced by multiple hypoxia-related
components, including VEGF receptor and calcium channel
transactivation (Suh and Han, 2013; Ancey et al., 2018). Recently,
the same researchers (Ancey et al., 2018) have demonstrated
the actions of Glut-1 and Glut-3 in enhancing cancer cell
metabolism. Simpson et al. (2008) demonstrated that, as glucose
transporters, Glut-1 and Glut-3 expression is up regulated to
increase glucose uptake and ultimately increase HIF-1 driven
glycolysis. Furthermore, earlier work in an erythroleukemia
mouse model demonstrating that Glut-1 expression is positively
related to resistance to multiple anti-cancer therapies, including
vincristine (Trendowski et al., 2015). Both Glut-1 and Glut-3
are overexpressed in human tumors, with Glut-1 expressed with
greater frequency than Gut-3. However, the Glut-3 type is the
major glucose transporter expressed in human brain tumors of
glial origin (Simpson et al., 2008). Subsequently, other researchers
demonstrated a positive relationship in HIF-1α and Glut-3
expression in human glioma tumors, by immunohistochemistry
and western blotting (Liu et al., 2009). These markers, HIF-
1α and Glut-3, show a positive correlation with the grade of
glioma and there is evidence to support a relationship between
these markers and tumor formation and rate of progression. On
this basis, we can conclude that the presence and level of these
markers are robust and valid reporters for glioma development
and growth (Liu et al., 2009).
THE ROLE OF HYPOXIA IN RESISTANCE
TO CONVENTIONAL CHEMO- AND
RADIATION THERAPY
There is a significant body of evidence that demonstrates
hypoxia-induced therapeutic resistance (Trédan et al., 2007;
Khawar et al., 2015). In part, this association may be due to
the fact that many anticancer drugs are large molecules, which
are not able to diffuse to target tissue due to the poorly formed
vasculature. Moreover, hypoxic tumor cells are distant from the
blood supply and as a result only a proportion of them may be
exposed to a lethal dose of a cytotoxic agent (Trédan et al., 2007).
Tumor-associated hypoxia is shown to promote drug
resistance, specifically through increased expression and
amplification of the genes for the P-glycoprotein (P-gp)
membrane exporter. The consequence of increased expression
of P-gp is a reduction in cellular sequestration of multiple
anti-cancer drugs, and it is likely that this pathway is correlated
with tumor resistance to topoisomerase II-targeted drugs
(Trédan et al., 2007). Radioresistance is the negative effect of
tumor hypoxia that impacts the ability of radiotherapy to treat
tumors (Harrison et al., 2002; Moeller et al., 2007). Tumor
sensitivity to radiation exposure rapidly declines when the local
pO2 is less than 25–30 mmHg (3.3–3.9%) (Ruan et al., 2009).
Oxygen enhancement is the term used to describe the process
by which hypoxia confers radioresistance within a tumor. As
a consequence of radiotherapy, via ionization or associated
with oxygen-favoring radicals, such as hydroxyl radical and
superoxide, resulting from ionization of water surrounding
DNA, tumor cell DNA is damaged. In short, radiotherapy results
in DNA breakages, and failure by the cell to repair the damage
frequently results in cell death. In hypoxia situations, the cells
have increased ability to conduct repairs to the disrupted DNA,
while in the presence of oxygen; stable peroxides are created
between oxygen and the free DNA ends, which are substantially
more resistant to cellular repair (Hu and Harrison, 2005; Hall
and Giaccia, 2006; Ruan et al., 2009). Resistant tumor cells
can remain viable after treatment, which leads to resistant
subpopulations of cells and poor local control for the patient
(Moeller et al., 2007). In addition, there is an association between
HIF-1, the tumor blood vessel network, and radiation resistance
(Moeller et al., 2004), inasmuch as HIF-1 activity is influenced
by radiation. The activity of HIF-1 in a tumor can nearly
double 24–28 h after exposure to radiation. This phenomenon is
restricted to in vivo tests only, as it relies on essential input from
the tumor microenvironment (Moeller et al., 2007). Following
radiotherapy, tumors may undergo a transient rise in oxygen
tension, or reoxygenation, due to the reduction in diffusion-
limited (chronic) hypoxia as a consequence of cytoreduction
(Bayer and Vaupel, 2012). Subsequently, radiation-induced
re-oxygenation of hypoxic tumor cells leads to the production
of ROS that induce HIF-1, which, in turn, activates the
expression of cytokines, including VEGF and basic fibroblast
growth factor (bFGF), which confer radio-protective effects on
neighboring endothelial cells. Ultimately, this leads to inhibition
of endothelial apoptosis via induction of anti-apoptotic signals
to tumor blood vessels, promoting an additional mechanism of
radiation resistance (Moeller et al., 2007; Zhou et al., 2017).
CONCLUSION
Tumor cells have three major specifications, namely, heightened
energy generation, adequate macromolecular biosynthesis and
redox balance preservation, which must be balanced by
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the metabolic adaptations. These processes must be closely
investigated to identify the weakness in tumor metabolic
pathways and thus formulate effective treatment strategies.
Creation of therapeutic approaches capable of retarding tumor
progression, enhancing treatment response and achieving
favorable clinical results is the overarching aim. Furthermore,
an enhanced appreciation of tumor metabolism, specifically
the relationship between aerobic glycolysis and adaptive
malignant growth, may direct the advancement of tumor-
targeting and normal tissue-sparing neo-therapeutics. Driving
permissive cellular and tissue survival factors, hypoxia-led
metabolic change in cancers permits enhanced malignancy,
and subsequently results in lower survival rates via enhanced
therapy resistance and augmented metastatic capacity. Clarifying
the processes by which hypoxia drives metabolic change
at the cellular level will facilitate a strategic focus on the
defined pathways, ultimately ensuring death of the tumor
cells.
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